Back to search results

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Sickle Cell Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Alabama Birmingham, Birmingham, Alabama, United States

    Contact: Study coordinator (Emily Burke) · eduke@uabmc.edu · +1 205 801 3411
    Contact: Principal Investigator (Julie Kanter-Washko)

  • Quotient Sciences Sea View, Miami, Florida, United States

  • Boston Childrens Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Nadia Tarhini) · nadia.tarhini@childrens.harvard.edu · +1 617 355 4278
    Contact: Principal Investigator (Matthew M Heeney)

  • East Carolina University, Greenville, North Carolina, United States

    Contact: Study coordinator (Kelly Martin) · martinke21@ecu.edu
    Contact: Principal Investigator (Darla Liles)

  • Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Kevin Dougherty) · doughertk8@chop.edu · +1 215 590 9959
    Contact: Principal Investigator (Alexis A Thompson)

  • Lifespan, Providence, Rhode Island, United States

    Contact: Study coordinator (Asher Dillman) · adillmann@brownhealth.org · +1 401 444 5328
    Contact: Principal Investigator (Patrick Mc Gann)

  • UT Health Science Center, Houston, Texas, United States

    Contact: Study coordinator (Eyuel Baherey) · Eyuel.L.Baherey@uth.tmc.edu
    Contact: Principal Investigator (Modupe Idowu)

  • Novartis Investigative Site, Ankara, Sihhiye-Altindag, Turkey (Türkiye)

  • Novartis Investigative Site, Adana, Yuregir, Turkey (Türkiye)

View source on ClinicalTrials.gov(opens in a new tab)